이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Daewoong wins approval for stem cell processing facility in Indonesia

Collected: 2024.02.14

Distributed: 2024.02.15

Source: Go Direct

이미지 확대

Daewoong Biologics Indonesia (DBI) [Courtesy of Daewoong Pharmaceutical]

South Korea’s Daewoong Pharmaceutical Co. announced Tuesday that its subsidiary in Indonesia, has won approval from the local health authority for its stem cell processing facility.

The approval is expected to allow Daewoong Biologics Indonesia (DBI) to manufacture and process stem cells for distribution to hospitals, clinics, and other healthcare organizations.

DBI, established by Daewoong Pharmaceutical in 2021, operates a cell therapy production plant, a cosmetics production plant, and a laboratory in the Jababeka Industrial Estate in Cikarang, Indonesia.

Daewoong Pharmaceutical plans to transfer home-grown cutting-edge cell therapy development technology to DBI and foster collaboration with the Yongin Cell Therapy Center to facilitate mutual growth in Indonesia’s regenerative medicine industry.

By Woo Je-yoon and Han Yubin

List

Previous: SK telecom brings veterinary support solution to Australia

Next: Hanwha secures defense collaboration with Saudi Arabia